Annovis Bio has regained compliance with NYSE listing standards by lifting its average global market capitalization and stockholders’ equity above the $50 million thresholds within 12 months. The company now retains its NYSE listing and is directing efforts toward pivotal Phase 3 Alzheimer’s topline data readout and impending regulatory submissions.
On May 26, 2026, Annovis confirmed it has regained compliance with NYSE Section 802.01B by restoring its average global market capitalization and stockholders’ equity above the $50 million thresholds.
Following the NYSE’s March 2025 notice, Annovis implemented a cure plan that included targeted capital initiatives and strategic measures, submitting quarterly progress updates to exceed required metrics within a 12-month period.
With its NYSE listing secured, Annovis Common Stock will remain traded under its symbol, allowing the company to focus on advancing its clinical pipeline toward the pivotal Phase 3 Alzheimer’s topline data readout and upcoming regulatory submissions.
